中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 57-62

The level of HBV cccDNA in liver tissue and its clinical significance in patients in the convalescence stage of hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.12449/JCH250109
  • a.

    Department of Chronic Liver Diseases The Ninth Hospital of Nanchang, Nanchang 330002, China

  • b.

    Department of Pathology, The Ninth Hospital of Nanchang, Nanchang 330002, China

More Information
  • Corresponding author: XU Long， xulong791@126.com （ORCID： 0009-0004-9918-3237）
  • Received Date: 2024-05-17
  • Accepted Date: 2024-07-10
  • Published Date: 2025-01-25
    Abstract
  •   Objective  To investigate the expression level of HBV cccDNA in patients in the convalescence stage of hepatitis B virus-related acute-on-chronic liver failure （HBV-ACLF） and its correlation with HBV markers and liver histopathological changes.  Methods  A total of 30 patients in the convalescence stage of HBV-ACL who were hospitalized in The Ninth Hospital of Nanchang from January 2015 to October 2023 were enrolled as liver failure group， and 9 patients with chronic hepatitis B （CHB）， matched for sex and age， were enrolled as control group. The content of HBV cccDNA in liver tissue was measured， and its correlation with clinical data and laboratory markers was analyzed. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and a one-way analysis of variance or the Kruskal-Wallis H test was used for comparison between multiple groups； the Fisher’s exact test was used for comparison of categorical data between groups. A Spearman correlation analysis was performed.  Results  The liver failure group had a significantly lower content of HBV cccDNA in liver tissue than the control group （-0.92±0.70 log10 copies/cell vs -0.13±0.91 log10 copies/cell， t=2.761， P=0.009）. In the liver failure group， there was no significant difference in the content of HBV cccDNA in liver tissue between the HBeAg-positive patients and the HBeAg-negative patients （P>0.05）； there was no significant difference in the content of HBV cccDNA in liver tissue between the patients with different grades （G0-G2， G3， and G4） of liver inflammatory activity （P>0.05）； there was no significant difference in the content of HBV cccDNA in liver tissue between the patients with different stages （S0-S2， S3， and S4） of liver fibrosis （P>0.05）； there was no significant difference in the content of HBV cccDNA in liver tissue between the patients with negative HBV DNA and those with positive HBV DNA （P>0.05）. For the liver failure group， the content of HBV cccDNA in liver tissue was positively correlated with the content of HBV DNA in liver tissue （r=0.426， P=0.043） and was not significantly correlated with the content of HBV DNA in serum （P>0.05）.  Conclusion  There is a significant reduction in the content of HBV cccDNA in liver tissue in the convalescence stage of HBV-ACLF. HBV cccDNA exists continuously and stably in liver tissue and can better reflect the persistent infection and replication of HBV than HBV DNA in serum and liver tissue.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    MOREAU R, GAO B, PAPP M, et al. Acute-on-chronic liver failure: A distinct clinical syndrome[J]. J Hepatol, 2021, 75( Suppl 1): S27- S35. DOI: 10.1016/j.jhep.2020.11.047.
    [2]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [3]
    SARIN SK, CHOUDHURY A, SHARMA MK, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL): An update[J]. Hepatol Int, 2019, 13( 4): 353- 390. DOI: 10.1007/s12072-019-09946-3.
    [4]
    ZHANG B, DILIHUMAER ZYE, ZHANG SY, et al. Progress on pathogenesis and medical treatment of hepatitis B virus-related chronic and acute liver failure[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 1): 28- 33. DOI: 10.3969/j.issn.1674-7380.2023.01.005.

    张斌, 迪丽胡玛尔·扎依尔, 张诗雨, 等. 乙型肝炎相关慢加急性肝衰竭发病机制及治疗进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 1): 28- 33. DOI: 10.3969/j.issn.1674-7380.2023.01.005.
    [5]
    GU WY, XU BY, ZHENG X, et al. Acute-on-chronic liver failure in China: Rationale for developing a patient registry and baseline characteristics[J]. Am J Epidemiol, 2018, 187( 9): 1829- 1839. DOI: 10.1093/aje/kwy083.
    [6]
    WURSTHORN K, LUTGEHETMANN M, DANDRI M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B[J]. Hepatology, 2006, 44( 3): 675- 684. DOI: 10.1002/hep.21282.
    [7]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Inf, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [8]
    VERRIER ER, COLPITTS CC, BACH C, et al. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses[J]. Hepatology, 2016, 63( 1): 35- 48. DOI: 10.1002/hep.28013.
    [9]
    TSUKUDA S, WATASHI K. Hepatitis B virus biology and life cycle[J]. Antiviral Res, 2020, 182: 104925. DOI: 10.1016/j.antiviral.2020.104925.
    [10]
    MACOVEI A, PETRAREANU C, LAZAR C, et al. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment[J]. J Virol, 2013, 87( 11): 6415- 6427. DOI: 10.1128/JVI.00393-13.
    [11]
    XIA YC, GUO HT. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential[J]. Antiviral Res, 2020, 180: 104824. DOI: 10.1016/j.antiviral.2020.104824.
    [12]
    YAN Y, ALLWEISS L, YANG DL, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8( 1): 879- 894. DOI: 10.1080/22221751.2019.1625728.
    [13]
    LUTGEHETMANN M, VOLZ T, KÖPKE A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice[J]. Hepatology, 2010, 52( 1): 16- 24. DOI: 10.1002/hep.23611.
    [14]
    ALLWEISS L, VOLZ T, GIERSCH K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut, 2018, 67( 3): 542- 552. DOI: 10.1136/gutjnl-2016-312162.
    [15]
    WEN B, YUAN J, LI XH, et al. The clinical features in chronic severe hepatiti B patients with HBeAg-positive and HBeAg-negative[J]. Chin J Prim Med Pharm, 2010, 17( 1): 50- 52. DOI: 10.3760/cma.j.issn.1008-6706.2010.01.024.

    文彬, 袁静, 李晓鹤, 等. HBeAg阳性与HBeAg阴性慢性重型乙型肝炎死亡患者的临床特征比较[J]. 中国基层医药, 2010, 17( 1): 50- 52. DOI: 10.3760/cma.j.issn.1008-6706.2010.01.024.
    [16]
    RAO M, LU W, ZHANG ZQ, et al. The relationship among HBV cccDNA, HBV total DNA in liver tissue and serum HBV DNA and their clinic-pathological significances in patients with chronic hepatitis B[J]. Chin Hepatol, 2012, 17( 6): 381- 384. DOI: 10.14000/j.cnki.issn.1008-1704.2012.06.013.

    饶敏, 陆伟, 张占卿, 等. 慢性乙型肝炎患者肝组织HBV cccDNA、总HBV DNA与血清HBV DNA的相关性及其与临床的关系[J]. 肝脏, 2012, 17( 6): 381- 384. DOI: 10.14000/j.cnki.issn.1008-1704.2012.06.013.
    [17]
    XIE YL, HUANG WL, DU J, et al. The relationship between HBV cccDNA of chronic hepatitis B patients liver tissues andserum HBsAg and liverinjury[J]. China J Mod Med, 2014, 24( 22): 25- 27.

    谢元林, 黄维亮, 杜杰, 等. 乙肝患者肝组织cccDNA与血清HBsAg及肝损伤的关系[J]. 中国现代医学杂志, 2014, 24( 22): 25- 27.
    [18]
    LIU XY, CHEN J, XIAO L, et al. Clinical features of HBV-associated acute-on-chronic liver failure induced by discontinuation of nucleoside analogues[J]. J Clin Hepatol, 2016, 32( 9): 1766- 1769. DOI: 10.3969/j.issn.1001-5256.2016.09.028.

    刘晓燕, 陈婧, 肖珑, 等. 停用核苷和核苷酸类药物诱发HBV相关慢加急性肝衰竭患者的临床特点分析[J]. 临床肝胆病杂志, 2016, 32( 9): 1766- 1769. DOI: 10.3969/j.issn.1001-5256.2016.09.028.
    [19]
    ZHANG X, LU W, ZHENG Y, et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection[J]. J Clin Invest, 2016, 126( 3): 1079- 1092. DOI: 10.1172/JCI83339.
    [20]
    CHEN JL, YUAN ZH. Influence of interferon and nucleos(t) ide analogues on HBV cccDNA and functional cure of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35( 6): 1181- 1187. DOI: 10.3969/j.issn.1001-5256.2019.06.002.

    陈捷亮, 袁正宏. 干扰素和核苷(酸)类似物治疗对HBV cccDNA的影响与慢性乙型肝炎的功能性治愈[J]. 临床肝胆病杂志, 2019, 35( 6): 1181- 1187. DOI: 10.3969/j.issn.1001-5256.2019.06.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (120) PDF downloads(23) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return